2023 World Conference on Lung Cancer (Posters)-EP13.01. pN Stage Predicts Survival Benefits of Postoperative Radiotherapy in Combined Small Cell Lung Cancer Patients after Surgery

EP13.01. pN Stage Predicts Survival Benefits of Postoperative Radiotherapy in Combined Small Cell Lung Cancer Patients after Surgery - PDF(Slides)

Back to course

Pdf Summary

A study conducted by researchers at Shanghai Chest Hospital in China aimed to determine the value of postoperative radiotherapy (PORT) in patients with combined small cell lung cancer (C-SCLC) who underwent surgical resection. The study collected data from 240 C-SCLC patients who had surgery between 2009 and 2019 and used propensity score matching to balance the characteristics of patients who did and did not receive PORT.<br /><br />The results showed that PORT did not have a significant impact on patients with positive lymph nodes. However, it significantly improved disease-free survival (DFS) and overall survival (OS) in patients with pN1 and pN2 stage C-SCLC.<br /><br />The study found that 33.75% of the patients received PORT, and after matching, a total of 163 patients were analyzed. The median DFS and OS for all C-SCLC patients in the study were 36.8 and 52.4 months, respectively.<br /><br />Multivariate Cox regression analysis identified pN stage, PORT, serum NSE, and CA125 levels as independent risk factors for survival in C-SCLC patients. Additionally, survival analysis confirmed that patients who received PORT had a more favorable OS.<br /><br />Overall, the study suggests that PORT has survival benefits for C-SCLC patients with positive lymph nodes after surgical resection. These findings can help guide clinical decisions regarding the use of PORT in this patient population.

Asset Subtitle

Wei Zhang

Meta Tag

Speaker Wei Zhang

Topic SCLC & Neuroendocrine Tumors: Biomarkers & Radiomics

Keywords

postoperative radiotherapy

combined small cell lung cancer

surgical resection

positive lymph nodes

disease-free survival

overall survival

pN1 stage

pN2 stage

serum NSE

CA125 levels